Well, September is no stranger to volatility, and the swings have already begun. After Tuesday's steep sell-off, all three major averages, they're rebounding from some earlier losses. But a busy few days of econ data ahead, including the August jobs report on Friday, that could further complicate the path forward. For more on how to position yourself for a volatile September, we've got Christian Magoon, founder and CEO of Amplify ETFs, who's joining us as part of this week's ETF report brought to you by Invesco QQQ. Christian, great to see you. Great to catch up once again. So, first and foremost here, as we're tracking some of the volatility, some of the swings, as we've now crept back into positive territory, we'll see if we can hold on to that as we go on throughout some of the economic data readings the rest of this week. What are the ETF plays that investors would be apt to keep on their docket?

Yeah, hey, Brad, good to see you. Thanks for having me on. And, you know, I think one of the areas going into September and October, you know, this volatile period in the fall that's really accentuated during election season, would be looking at your core equity position, and instead of maybe going just 100% long, looking at a high-quality covered call equity strategy that would give you kind of the benefit of higher quality names, but then also the ability to have covered call income from those names, which acts as a hedge during kind of downward market environments. And also kind of benefits in terms of more option income as markets become more volatile. So I think that would be a great complement or even an alternative to a long-only equity portfolio. We have an ETF, DIVO, D-I-V-O, and, you know, it's five-star rated, and does just that. Owns high-quality, blue chip, dividend paying stocks. It's actively managed, and then the managers have the ability to write covered calls on the portfolio. So you're not just dependent on capital appreciation for your total return. You also get dividend income and option income. We think that's kind of a great way to have some a belt and suspenders, so to speak, going into this volatile fall season.

You know, one of the sexiest trades in the market to talk about has been this AI trade, and the AI theme, and all the ETFs that really surround it. But one of the other sexy trades is this weight loss drug market for both health and for any other reasons that people are tapping into some of the GLP-1s and the associated type of solutions that are being put into market here. This is something that you're tracking. How are you playing the weight loss drug market via ETFs?

Yeah, so we launched the first ETF that tracks this GLP-1 weight loss drug category. Uh, that's the Amplify, uh, uh, drug, uh, weight loss drug and treatment ETF. Ticker THNR, thinner. So it's an index-based ETF. The only index-based ETF to track this segment that owns the companies that are manufacturing GLP-1s and that are in clinical trials on the GLP-1 side. In addition, it owns some of the enablers of this technology, the companies that are making the injection pens, doing the testing or third-party manufacturing of the drugs. So, you know, GLP-1 drugs could be the largest category of drugs ever because of the total addressable market, right? So many people think of them as just weight loss drugs, but now, Brad, they're being prescribed, people have cardiovascular issues, also for diabetes. And when you start looking at who qualifies for that just in the US, it's close to 70% of the population. Now, you know, these drugs have been in short supply. The supply is starting to ramp up. Insurance coverage is starting to become more robust. So we think that this is a great kind of early innings play for thematic investors, and maybe has kind of the, uh, the, uh, appeal to be able to withstand some of this market volatility because we expect to see continued good news from clinical trials and breakthroughs in this space. And, you know, by that I mean not just injecting drugs, maybe using them in pill format, maybe only being able to take a pill once a week or once a month. And, of course, other types of uses beyond kind of the big three, which includes maybe Alzheimer's, sleep apnea, and addictive behaviors. So this GLP-1 trend is a big deal, and we think our ETF, THNR, thinner, uh, is a great way to play it from an index standpoint. You know, why choose one or two stocks? Instead, you can own the basket that's professionally selected.

And just lastly, while we have you here, another core theme that you're tracking is cybersecurity here. There's been a lot of movements within cyber as of late, whether that be CrowdStrike, or what we've heard from some of the other entities that are really trying to make sure that even as generative AI means more data centers, more powerful data centers, that there's more cybersecurity put around that here. What's the play there?

Yeah, we really think this is a resilient theme, Brad, going into the election. I mean, there's a lot of geopolitical issues, both internally and externally. Uh, this morning the FBI kind of announced a North Korean threat against companies, including, I guess, Amplify ETFs. Companies that are involved with cryptocurrency, ETFs and cryptocurrency funds, of which we have exposure there. So, uh, you know, these cyber attacks and criminals are becoming more sophisticated. Uh, this is an essential spend in the technology area. So our ETF, HACK, H-A-C-K, is the first cybersecurity ETF to launch. It's the original one here in the US, index-based, and again, it owns kind of the broad-based companies in this sector, and we think the demand for this is very inelastic. Uh, companies, governments, individuals, we can't not spend on cybersecurity. The risks are too high. So we think this is a theme that is really worth taking a look at. For those who are technical and traders and looking at the chart, if you look over the last three years, there is seemingly a cup and handle forming. So we could see a breakout. We're at relative highs here for cybersecurity, a little bit off, but again, we think a resilient theme to kind of take you through the fall and into the next year.

Christian Magoon, who is the founder and CEO of Amplify ETFs. Christian, great to catch up with you once again. Thanks so much for taking the time.

Thanks, Brad.